urea has been researched along with Hallucinations in 20 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 9.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| " One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis." | 7.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 6.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 5.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of pimavanserin for the treatment of hallucinations and delusions of Parkinson's disease psychosis (PDP)." | 4.95 | Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. ( Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM, 2017) |
| "To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis." | 4.95 | The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. ( Andreason, P; Atrakchi, A; Avila, AM; Farchione, T; Mathis, MV; Muoio, BM; Temple, RJ, 2017) |
| " Pimavanserin is the first FDA approved drug for the treatment of hallucinations and delusions associated with PDP." | 4.95 | Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. ( Kianirad, Y; Simuni, T, 2017) |
| "Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis." | 4.93 | Pimavanserin: First Global Approval. ( Markham, A, 2016) |
| " Pimavanserin is approved for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis (PDP) as a 34-mg capsule formulation." | 4.12 | In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered. ( Adegbenle, YH; Bokser, AD; Norton, JC; Stoisavljevic, V, 2022) |
| " One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis." | 3.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
| "The terms "Parkinson's disease psychosis", "Parkinson psychosis," "neurodegenerative psychosis", and "dopamine psychosis" were among the keywords used in the search." | 2.82 | Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. ( Bautista-Sandoval, MJ; Bermúdez, V; Chacín, M; Chávez-Castillo, M; Cudris-Torres, L; Duran, P; Medina-Ortiz, O; Ortega, Á; Palmar, J; Riaño-Garzón, M; Rojas, M; Salazar, J, 2022) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 2.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology." | 2.58 | Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. ( Ondo, WG; Panchal, SC, 2018) |
| "Sleep paralysis is a state of involuntary immobility occurring at sleep onset or offset, often accompanied by uncanny "ghost-like" hallucinations and extreme fear reactions." | 2.58 | The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. ( Jalal, B, 2018) |
| " Safety was evaluated from adverse events (AEs), clinical laboratory results, motor symptoms, electrocardiograms (ECG), and mortality." | 1.56 | Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. ( Abler, V; Azulay, JP; Ballard, CG; Demos, G; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, S; Kreitzman, DL; Liu, IY; Norton, JC; Stankovic, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bokser, AD | 1 |
| Adegbenle, YH | 1 |
| Stoisavljevic, V | 1 |
| Norton, JC | 2 |
| Rojas, M | 1 |
| Chávez-Castillo, M | 1 |
| Duran, P | 1 |
| Ortega, Á | 1 |
| Bautista-Sandoval, MJ | 1 |
| Salazar, J | 1 |
| Riaño-Garzón, M | 1 |
| Chacín, M | 1 |
| Medina-Ortiz, O | 1 |
| Palmar, J | 1 |
| Cudris-Torres, L | 1 |
| Bermúdez, V | 1 |
| Ballard, CG | 1 |
| Kreitzman, DL | 1 |
| Isaacson, S | 1 |
| Liu, IY | 1 |
| Demos, G | 1 |
| Fernandez, HH | 1 |
| Ilic, TV | 1 |
| Azulay, JP | 1 |
| Ferreira, JJ | 1 |
| Abler, V | 1 |
| Stankovic, S | 2 |
| Cummings, JL | 2 |
| Devanand, DP | 2 |
| Stahl, SM | 1 |
| Tariot, PN | 1 |
| Soto-Martin, ME | 1 |
| Ballard, C | 1 |
| Erten-Lyons, D | 1 |
| Sultzer, DL | 1 |
| Weintraub, D | 1 |
| McEvoy, B | 1 |
| Youakim, JM | 1 |
| Foff, EP | 1 |
| Bozymski, KM | 1 |
| Lowe, DK | 1 |
| Pasternak, KM | 1 |
| Gatesman, TL | 1 |
| Crouse, EL | 1 |
| Mathis, MV | 1 |
| Muoio, BM | 1 |
| Andreason, P | 1 |
| Avila, AM | 1 |
| Farchione, T | 1 |
| Atrakchi, A | 1 |
| Temple, RJ | 1 |
| Kianirad, Y | 1 |
| Simuni, T | 1 |
| Sahli, ZT | 1 |
| Tarazi, FI | 1 |
| Panchal, SC | 1 |
| Ondo, WG | 1 |
| Webster, P | 1 |
| Jalal, B | 1 |
| Nasrallah, HA | 1 |
| Fedora, R | 1 |
| Morton, R | 1 |
| Traynor, K | 1 |
| Markham, A | 1 |
| ELSASSER, G | 1 |
| STOLK, DP | 1 |
| Scott, BB | 1 |
| Pieri, L | 1 |
| Keller, HH | 1 |
| Burkard, W | 1 |
| Da Prada, M | 1 |
| Sargant, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis[NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease[NCT00550238] | Phase 3 | 459 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The endpoint of time from randomization to discontinuation from the DB period for any reason (other than termination of the study by the sponsor) was compared between treatment groups using a Cox regression model. The treatment effect was measured by the HR. (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
"The time from randomization to relapse in the DB period was compared between treatment groups using a Cox regression model. The treatment effect was measured by the hazard ratio (HR).~Relapse was defined as (1) ≥30% increase in SAPS-H+D total score from DB baseline (BL) and CGI-I score ≥6 relative to DB BL, (2) treatment with antipsychotic for dementia-related delusions/hallucinations, (3) treatment/study discontinuation due to lack of efficacy, and/or (4) hospitalization for worsening dementia-related psychosis.~SAPS-H+D is a 20-item scale; the total score is the sum of the 20 item scores (range 0-100); higher scores denote more severe symptoms. CGI-I is a clinician-rated 7-point scale to rate improvement in hallucinations/delusions relative to BL (range 1-7); higher scores denote less improvement or worsening.~A pre-specified IA was conducted after accrual of 40 adjudicated relapse events. The prespecified stopping criterion was met; the study was stopped for efficacy." (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug) (NCT00550238)
Timeframe: From first to last study drug dose plus 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pimavanserin | 180 |
9 reviews available for urea and Hallucinations
| Article | Year |
|---|---|
Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
Topics: Antipsychotic Agents; Dopamine; Hallucinations; Humans; Illusions; Parkinson Disease; Psychotic Diso | 2022 |
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; United Stat | 2017 |
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Delusions; Drug Inverse Agonism; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Topics: Animals; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Ps | 2018 |
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic D | 2018 |
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
Topics: Animals; Dopamine; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neuropharmacol | 2018 |
Pimavanserin: First Global Approval.
Topics: Antipsychotic Agents; Delusions; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Halluc | 2016 |
2 trials available for urea and Hallucinations
| Article | Year |
|---|---|
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations | 2021 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
9 other studies available for urea and Hallucinations
| Article | Year |
|---|---|
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered.
Topics: Adult; Aged; Hallucinations; Humans; Piperidines; Urea; Water | 2022 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Male; Middle Aged; Pa | 2020 |
Pimavanserin evaluated by the FDA.
Topics: Antipsychotic Agents; Delusions; Drug Evaluation; Hallucinations; Humans; Parkinson Disease; Piperid | 2018 |
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Hu | 2019 |
Pimavanserin approved for Parkinson's-related hallucinations, delusions.
Topics: Antiparkinson Agents; Delusions; Drug Approval; Drug Labeling; Hallucinations; Humans; Parkinson Dis | 2016 |
[Hallucinations in chronic misuse of adaline; manifestations and clinical aspects of exogenic psychotic syndromes].
Topics: Bridged-Ring Compounds; Hallucinations; Humans; Mental Disorders; Piperidines; Psychotic Disorders; | 1956 |
[Chronic hallucinations with paranoid features due to misuse of carbromal (Diacid, Adaline)].
Topics: Bridged-Ring Compounds; Bromine; Hallucinations; Humans; Hypnotics and Sedatives; Paranoid Disorders | 1962 |
Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis.
Topics: Animals; Brain; Cyclic AMP; Dopamine; Ergolines; Hallucinations; Homovanillic Acid; Humans; Hydroxyi | 1978 |
Safety of combined antidepressant drugs.
Topics: Antidepressive Agents; Dibenzazepines; Drug Synergism; Hallucinations; Humans; Male; Pentobarbital; | 1971 |